A structural modification study of procarbazine.
Eight analogues of the antineoplastic compound procarbazine were prepared by varying one portion of the molecule, keeping either the methylhydrazinomethyl or the N-(1-methylethyl)benzamido portion of procarbazine intact. Preliminary screening results indicated that none of the analogues tested in leukemias L1210 and P388 were as active as the original compound.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011344:Procarbazine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology
D000970:Antineoplastic Agents; D011344:Procarbazine